Unknown PHASE2 NCT00003327

Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer

Sponsor: Theradex

Conditions Head and Neck Cancer

Interventions paclitaxel

Updated 5 times since 2017 Last updated: Jul 23, 2008 Started: Sep 30, 1997

This PHASE2 trial investigates Head and Neck Cancer and is currently ongoing. Theradex leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Sep 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theradex

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Baltimore, United States , Baton Rouge, United States , Binghamton, United States , Charlotte, United States , Danville, United States , Dayton, United States , Decatur, United States , Fresno, United States , Hollywood, United States and 10 more locations